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ABSTRACT
Cancer cells exhibit altered metabolism including aerobic glycolysis that 
channels several glycolytic intermediates into de novo purine biosynthetic pathway. 
We discovered increased expression of phosphoribosyl amidotransferase (PPAT) 
and phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole 
succinocarboxamide synthetase (PAICS) enzymes of de novo purine biosynthetic 
pathway in lung adenocarcinomas. Transcript analyses from next-generation 
RNA sequencing and gene expression profiling studies suggested that PPAT and 
PAICS can serve as prognostic biomarkers for aggressive lung adenocarcinoma. 
Immunohistochemical analysis of PAICS performed on tissue microarrays showed 
increased expression with disease progression and was significantly associated 
with poor prognosis. Through gene knockdown and over-expression studies 
we demonstrate that altering PPAT and PAICS expression modulates pyruvate 
kinase activity, cell proliferation and invasion. Furthermore we identified genomic 
amplification and aneuploidy of the divergently transcribed PPAT-PAICS genomic 
region in a subset of lung cancers. We also present evidence for regulation of both 
PPAT and PAICS and pyruvate kinase activity by L-glutamine, a co-substrate for 
PPAT. A glutamine antagonist, 6-Diazo-5-oxo-L-norleucine (DON) blocked glutamine 
mediated induction of PPAT and PAICS as well as reduced pyruvate kinase activity. In 
summary, this study reveals the regulatory mechanisms by which purine biosynthetic 
pathway enzymes PPAT and PAICS, and pyruvate kinase activity is increased and 
exposes an existing metabolic vulnerability in lung cancer cells that can be explored 
for pharmacological intervention.
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INTRODUCTION
Lung cancer is the leading cause of cancer-related 
deaths globally [1] with non-small cell lung cancer 
(NSCLC) accounting for 80% of all lung cancers [2, 3]. In 
the United States, the overall 5-year survival rate of lung 
cancer patients is 16% and more than 50% of the cases 
are diagnosed at advanced stages where curative treat-
ment is not possible. Genomic and gene  expression-based 
characterizations have resulted in improved molecular sub-
typing of lung cancer and identification of driver mutations 
including epidermal growth factor receptor (EGFR-
10–30%), Kirsten rat sarcoma viral oncogene homolog 
(KRAS-15–30%), and fibroblast growth factor receptor 1 
(FGFR1-20%), among others [4, 5].  Identification of 
EGFR activating mutations in its kinase domain led to 
the development of EGFR tyrosine kinase inhibitors, erlo-
tinib and gefitinib [5, 6]. Lung cancer patients harboring 
ALK gene fusions treated with crizotinib show similar 
positive response [7, 8]. In recent studies, identification 
of fusions of CD74-NRG1 that activate HER2:HER3 
signaling offered therapeutic possibilities for intractable 
mucinous lung cancers [9, 10]. Thus, well-defined molecu-
lar stratification has become essential for the development 
of targeted treatment for specific molecular subtypes of 
 cancers and personalized therapy.
Recent studies have identified various metabolic 
genes and associated metabolites that play a role in onco-
genesis. For example, IDH1 and IDH2 mutations confer 
altered enzyme properties producing  D-2-hydroxyglutarate 
and triggering oncogenesis [11, 12]. Our earlier studies 
revealed that the metabolite sarcosine and its biosynthetic 
enzyme, glycine N-methyltransferase (GNMT) were 
elevated in prostate cancer, while sarcosine dehydroge-
nase (SARDH) and pipecolic acid oxidase (PIPOX) that 
metabolize sarcosine, were reduced in prostate tumors 
[13, 14]. In addition, KRAS-mediated metabolic trans-
formation is known to activate the phosphate pentose 
pathway and hexosamine biosynthesis in pancreatic can-
cer [15]. Various oncogenes such as MYC have been 
shown to induce purine and pyrimidine biosynthesis 
genes including phosphoribosyl amidotransferase (PPAT), 
phosphoribosylaminoimidazole carboxylase, phospho-
ribosylaminoimidazole succinocarboxamide synthetase 
(PAICS), adenylosuccinate Lyase (ADSL), dihydrooro-
tate dehydrogenase (DHODH) and others [16, 17]. In 
addition, a yeast screen identified the purine biosynthetic 
gene PAICS as an anti-apoptotic oncogene [18]. Aerobic 
glycolysis, also known as the Warburg effect, is a well-
known metabolic aberration occurring during oncogenesis 
[19, 20] that allows cancer cells to siphon glycolytic inter-
mediates into anabolic pathways such as purine and 
pyrimidine biosynthesis to sustain increased cell prolifera-
tion [21]. These studies have advanced our understanding 
of driver genes and their effect on metabolic pathways 
involved in cancer and underscore the importance of meta-
bolic  dysregulation in cancer progression [22].
Purine nucleotides are synthesized through two 
distinct pathways, either de novo utilizing simple 
precursors like amino acids (glutamine, glycine and 
aspartate) and bicarbonate or through salvage of purine 
bases released by the hydrolytic degradation of nucleic 
acids and nucleotides. De novo purine biosynthesis 
requires 5-phosphoribosyl-1-pyrophosphate (PRPP) 
as a precursor and glutamine as co-substrate [23]. The 
initial committed step in this pathway is catalyzed 
by PPAT leading to production of 5-phosphoribosyl-
1-amine (5-PRA). PPAT is divergently transcribed from 
a locus that also encodes PAICS, another enzyme in 
the pathway that produces the intermediary metabolite 
N-succinyl-5-aminoimidazole-4-carboxamide-1-ribose-
5’-phosphate (SAICAR), known to activate pyruvate 
kinase isoform PKM2 under glucose-depleted condi-
tion [24]. After the initial committed step, in a series 
of enzymatic reactions, 5-PRA is converted to inosine 
monophosphate (IMP), the precursor for nucleotides 
adenosine monophosphate (AMP) and guanosine mono-
phosphate (GMP).
In this study, we demonstrate that de novo purine 
biosynthetic pathway enzymes PPAT and PAICS show 
increased expression in lung cancer and can serve 
as prognostic markers for patient survival. Further, 
our investigations indicate PPAT and PAICS genes 
are necessary for lung tumorigenesis. We show that 
PPAT and PAICS expression influences the pyruvate 
kinase activity. Finally, our results reveal glutamine 
mediated modulation govern PPAT and PAICS over-
expression.
RESULTS
De novo purine biosynthetic pathway genes are 
overexpressed in lung cancers
The de novo purine biosynthetic pathway 
involves multiple enzymatic steps that convert 
5-phosphoribosyl-1-pyrophosphate (PRPP) to  inosine 
monophosphate (IMP), a precursor for adenosine 
 monophosphate (AMP) and guanosine monophosphate 
(GMP) production. Many of the bifunctional enzymes cat-
alyze more than one step in the pathway. Recent studies 
have suggested that N-succinyl-5- aminoimidazole-4-
carboxamide-1-ribose-5’-phosphate (SAICAR), a product 
of the enzyme PAICS, is involved in activating pyruvate 
kinase PKM2 under glucose-depleting condition [24]. 
PKM2 is involved in increased aerobic glycolysis in 
cancer [25], and plays a non-metabolic role in cancer by 
modifying  histone H3 [26].
Our analysis using lung cancer gene expression 
profiling studies [27–33] available in the Oncomine 
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[ Oncomine™ Platform (Life  Technologies, Ann  Arbor, MI) 
was used for analysis and visualization] [34], showed 
 significantly increased expression of de novo purine 
 biosynthetic enzymes phosphoribosyl pyrophosphate 
amidotransferase (PPAT), phosphoribosylaminoimidazole 
carboxylase, phosphoribosylaminoimidazole succinocar-
boxamide synthetase (PAICS) (Fig. 1A; Supplementary 
Fig. S1A). The pyruvate kinase isoform PKM2 expression 
also showed increased expression in lung cancer. PPAT is 
involved in conversion of phosphoribosyl pyrophosphate 
(PRPP) to 5-phosphoribosylamine (5-PRA), a committing 
step in de novo purine synthesis. We further confirmed 
the increased expression of divergently transcribed PPAT, 
PAICS as well as PKM2 expression in lung cancer sam-
ples compared to normal samples by next-generation RNA 
sequencing (Fig. 1B) and quantitative RT-PCR analysis 
(Fig. 1C). We found no difference in PKM1 transcript 
expression (Fig. 1C). In addition, Affymetrix microarray 
analyses showed enhanced expression of PPAT, PAICS 
and PKM2 in poorly differentiated and stage 3 lung can-
cers (Supplementary Fig. S2A and S2B, respectively). 
Furthermore, our analysis showed that PPAT and PAICS 
are highly  expressed in the solid type of adenocarcinoma 
(Supplementary Fig. S2C) [35]. Analyses of other genes 
in de novo purine biosynthetic pathway enzymes (purino-
some) by oncomine (Supplementary  Fig. S1A) [33], gene 
expression from Seo et al [36] and TCGA datasets [37, 38] 
(Supplementary Fig. S1B), and next-generation RNA 
 sequencing (Supplementary Fig. S1C) showed increased 
expression of glycinamide ribonucleotide formyltrans-
ferase (a trifunctional enzyme with GARS, AIRS, GART 
activity) (GART), 5-aminoimidazole-4-carboxamide ribo-
nucleotide formyltransferase/IMP cyclohydrolase (ATIC) 
and phosphoribosylformylglycinamidine synthase (PFAS), 
but not adenylosuccinate lyase (ADSL) levels (Supple-
mentary Fig. S1C) [39]. Consistent with RNA expression, 
immunoblot analyses of PPAT, PAICS and PKM2 showed 
increased expression in cancer tissues compared to nor-
mal lung (Fig. 1D). However, PKM1 protein did not show 
increased expression in cancer similar to the transcript 
data (Fig. 1D).
PPAT and PAICS overexpression predicts poor 
survival in lung cancer
Kaplan-Meier analysis using transcript data for PPAT 
(Fig. 2A and 2B; Supplementary Fig. S2D) and PAICS 
revealed (Fig. 2C and 2D; Supplementary Fig. S2D) that 
they predict poor patient overall survival (OS) and disease 
free survival (DFS) with increased expression of these genes 
in two independent studies [35, 40]. Similarly, elevated 
PKM2 expression was also correlated with poor patient sur-
vival (Supplementary Fig. S3A) [35, 40]. Multivariate Cox 
model analysis (with gene, age,  gender, stage and differen-
tiation in the model) indicated that PAICS, PPAT and PKM2 
are also independently  associated with patient survival in 
lung  adenocarcinomas [HR 1.31 (1.05–1.64, P = 0.02), 
1.41 (1.03–1.92, P =  0.03), 1.60 (1.18–2.17, P = 0.002) 
for PAICS, PPAT or PKM2 respectively]. Thus, our obser-
vations demonstrate that expression of PPAT, PAICS as 
well as PKM2 serve as biomarkers of disease progression. 
 Tissue microarray analysis by immunohistochemistry (IHC) 
using specific antibodies against PPAT and PAICS showed 
increased staining in lung adenocarcinomas (Fig.  2E). Fur-
thermore, increased expression of PAICS is associated with 
poorly differentiated and more aggressive tumors (Fig. 2F). 
Kaplan-Meier analysis of those samples also revealed that 
increased PAICS protein expression related to poor patient 
survival (Fig. 2G) corroborating transcript (RNA) and 
 protein data. In addition, PKM2 showed increased expres-
sion in adenocarcinomas ( Supplementary Fig. S3B). Among 
the lung adenocarcinoma patients, smokers (both past and 
current) showed elevated PPAT and PAICS expression than 
non-smokers while PKM2 expression  levels were elevated in 
lung adenocarcinoma patients above age 60 (Supplementary 
Table S1). In order to  identify the  possible genomic events 
for PPAT and PAICS dysregulation, we performed fluores-
cence in situ  hybridization (FISH) with lung adenocarcinoma 
samples. We  discovered  aneuploidy and amplification in the 
 divergently transcribed locus of PPAT and PAICS in a sub-
set of lung adenocarcinoma (~3%  cases) and amplification 
in H661 lung cancer cell line (Fig. 2H). PPAT and PAICS 
are located within the 4q12 chromosomal segment that ear-
lier has been reported to be amplified in NSCLC [41]. Thus 
 amplification could be one of the potential mechanisms of 
increased expression of PPAT and PAICS in a subset of lung 
 adenocarcinomas.
PPAT, PAICS and PKM2 are critical for lung 
cancer cell proliferation and invasion
Normal cells fulfill their purine and pyrimidine 
requirements through the salvage pathway. Highly pro-
liferative and cancer cells are speculated to meet these 
requirements by activation of the de novo biosynthetic 
pathway [42]. We investigated the functional signifi-
cance of the de novo purine biosynthetic pathway genes 
PPAT and PAICS in lung cancer by loss-of-function 
analyses of these divergently transcribed and elevated 
in lung tumors. Additionally, we evaluated the func-
tional role of isoform of pyruvate kinase PKM2 in lung 
carcinomas since they were known to be activated in 
glucose depleted condition by the PAICS metabo-
lite SAICAR. We performed knockdown experiments 
using two independent gene-specific siRNAs. Of note 
we custom synthesized siRNA duplexes for the PKM2 
isoform [43]. Knockdown efficiency was confirmed 
by immunoblot analysis using specific antibodies 
(Fig. 3A, 3D and 3G) and by qRT-PCR (Supplementary 
Fig. S4A–S4C). Knockdown of each of these enzymes 
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Figure 1: De novo purine biosynthetic enzymes, PPAT & PAICS and pyruvate kinase isoform PKM2 are overexpressed 
in lung adenocarcinoma. A. Gene expression profiling [28, 30, 32, 33, 73–75] studies suggest enhanced expression of de novo purine 
biosynthetic enzymes PPAT & PAICS and PKM2 in multiple lung adenocarcinoma tissues. Expression is represented by a color scale 
highlighting down-regulation (blue), no alteration (white), and up-regulation (red) of transcripts. B. Quantitative measurement of PPAT, 
PAICS and PKM2 by Next-Generation RNA sequencing [RPKM (log2)] in lung adenocarcinomas [39]. C. Quantitative real-time polymerase 
chain reaction (qRT-PCR) measurement of PPAT, PAICS, PKM2 and PKM1 transcripts in lung adenocarcinomas. GAPDH transcript levels 
was used as control. D. Immunoblot analysis of lung adenocarcinoma tissue lysates (T) and matched normal samples (N) confirm increased 
expression of de novo purine biosynthetic enzymes PPAT, PAICS as well as specific PKM isoform PKM2 in lung cancer. PKM1 isoform 
expression was tested and did not show difference between normal and cancer tissues. β-actin was used as a loading control.
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Figure 2: Increased expression of PPAT and PAICS correlates with aggressive lung cancer and is amplified in a subset 
of lung cancer. A–D. Kaplan-Meier (K-M) analysis of survival time according to the PPAT and PAICS transcript levels as measured 
using Affymetrix oligonucleotide microarray datasets by Shedden et al., [35] Bild et al. [40], respectively. The CEL files of microarray 
data were normalized using Robust Multi-array Average (RMA) method. Expression was classified into low, medium and high expressing 
groups. Five year survival time was used for K-M calculations. E. Photomicrographs of PPAT and PAICS immunostaining in normal lung 
(left) and lung adenocarcinoma tissues (right) using PPAT and PAICS-specific antibodies. F. Tumors are classified into well differentiated, 
moderately differentiated and poorly differentiated class based on the total score of immunostaining. G. The immunohistochemistry on a 
lung adenocarcinoma tissue microarray was scored and K-M survival curve was calculated based on staining intensity. Like transcript levels, 
protein expression was also sub-grouped into three classes. H. FISH was performed in normal and lung tumor tissues (Adenocarcinomas) 
and H661 (large cell carcinoma).
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resulted in significant decrease in cell proliferation 
(Fig. 3B, 3E and 3H) and reduced cancer cell invasion as 
measured by Boyden chamber matrigel invasion assays 
(Fig. 3C, 3F and 3I), implicating a role for these genes 
in cancer cell growth and invasion. Our observation that 
PAICS knockdown inhibits cell proliferation concurs 
with similar observations in melanoma cells [18]. Cell 
cycle analyses revealed (Supplementary Fig. S5A and 
S5B) increase in S-phase population in the PPAT and 
PAICS knockdowns compared to controls. This obser-
vation is similar and consistent with slowing down of 
cell cycle when purine biosynthesis is blocked using 
anti-folates [44]. In addition, we found reduction in 
cell proliferation in H661, a large cell lung carcinoma 
cell line ( Supplementary Fig. S6A–S6C) that harbors 
PPAT and PAICS gene amplification (Fig. 2H) upon 
knockdown of PPAT, PAICS and PKM2. Knockdown 
efficiency was confirmed by immunoblot analysis using 
specific antibodies (Supplementary Fig. S6A–S6C, 
insets) and by qRT-PCR (Supplementary Fig. S4D–
S4F). These in vitro experiments underscore role of 
PPAT, PAICS and PKM2 in proliferation and invasion 
across a cross-section of lung cancers cells.
PPAT and PAICS expression modulate pyruvate 
kinase activity
Based on a published report that PAICS product, 
SAICAR acts as an allosteric activator of PKM2 under 
glucose depleted conditions [24], we hypothesized that 
apart from PAICS, PPAT expression also potentially can 
regulate pyruvate kinase activity. We first knocked down 
PKM2 and tested for Pyruvate Kinase (PK) activity in 
A549 lung adenocarcinoma cells. We observed a decrease 
in PK activity upon PKM2-targeted knockdown in normal 
medium compared to Non-T siRNA (Fig. 4A). Moreover 
PPAT and PAICS knockdowns also showed significant 
decrease in PK activity (Fig. 4B and 4C, respectively). 
A similar decrease in PK activity was observed with 
PAICS (Supplementary Fig. S7A and S7B) and PKM2 
(Supplementary Fig. S7C and S7D) knockdowns in H661 
cells. Furthermore, our data shows a role for PPAT, an 
enzyme upstream of PAICS in de novo purine biosynthesis 
pathway in  regulating PK activity.
Glutamine regulates PK activity, induces PPAT 
and PAICS expression
Glutamine plays a critical role in cancer  metabolism, 
[45, 46] and serves as a co-substrate for PPAT and PFAS. 
The final step of de novo pathway in which xanthine 
5′-monophosphate is converted to guanosine 5′-mono-
phosphate (GMP) also requires glutamine as amino 
donor [23]. We therefore tested the effect of glutamine 
both in regulation of PK activity as well PPAT and 
PAICS  expression. Glutamine deprivation  dramatically 
reduced A549 cell proliferation (Supplementary Fig. S8A) 
as observed  previously [47]. Glutamine deprivation 
 significantly reduced PK activity (Fig. 4D) and mod-
erately reduced PKM2 protein expression (Fig.  4E). 
Treatment with  similar concentrations of alanine failed 
to change PK activity over no glutamine controls 
( Supplementary  Fig.  S8B). In addition, pyruvate kinase 
activity and reduction in  expression of PPAT and PAICS by 
 glutamine  deprivation could be entirely restored by exog-
enous addition of glutamine in A549 cells (Fig. 4D and 
4E, respectively). We found similar, albeit less  dramatic 
effects of glutamine deprivation on cell  proliferation 
of H661 and H838 cells (Supplementary Fig. S8C and 
S8E, respectively), and PPAT and PAICS expression 
 (Supplementary Fig. S8D and S8F), suggesting one of 
several critical roles of  glutamine is in activating de novo 
purine biosynthesis pathway genes and altering  cancer 
cell metabolism. Furthermore, treating A549 cells with 
increasing concentration of  glutamine antagonist, L-diazo-
5-oxo-L-norleucine (DON) [48] reduced PK activity 
(Fig. 4F) and PPAT and PAICS  expression (Fig. 4G) 
even in presence of  glutamine that were comparable to 
glutamine starved controls.  Conversely, over-expression 
of PAICS in the benign lung cells,  BEAS-2B resulted 
in increased PK activity  (Supplementary Fig. 9A) and 
invasion (Supplementary Fig. 9B). Taken together, these 
results demonstrate that glutamine activates de novo 
purine biosynthetic  pathway genes PPAT and PAICS and 
increases pyruvate kinase  activity.
PPAT and PAICS play a role in lung tumor 
growth
Extending the in vitro studies described above, we 
next tested the role of PPAT and PAICS in two in vivo 
lung cancer xenograft models. We generated two inde-
pendent stable knockdowns of PPAT and PAICS in A549 
cells (Fig. 5A and 5B, inset) and used them in a chicken 
chorioallantoic membrane (CAM) assay that has been suc-
cessfully used as an in vivo model to faithfully recapitulate 
several features of oncogenesis including tumor growth, 
local invasion and metastasis [49–51]. A549 cells with 
stable knockdown of PPAT or PAICS showed reduction in 
CAM tumor growth compared to cells with non-targeting 
shRNA controls (Fig. 5A and 5B, respectively). Similarly, 
H23 (lung adenocarcinoma cells) with PAICS knock-
down (Supplementary Fig. S10A) showed reduced cell 
proliferation (Supplementary Fig. S10B) and a decrease 
in CAM tumor growth (Supplementary Fig. S10C). Next, 
we performed mouse xenograft experiments where athy-
mic nude mice were injected subcutaneously with PPAT 
and PAICS stable knockdown A549 cells and tumors were 
subsequently measured. A significant reduction both in 
tumor growth and weight was observed in both PPAT 
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Figure 3: PPAT, PAICS and PKM2 regulate cell proliferation and invasion in A549 lung adenocarcinoma cell lines. The 
knockdown of each gene was achieved using two independent siRNAs. A. PPAT gene specific, D. PAICS gene specific and G. PKM2 
isoform specific siRNAs were used for the knockdown. A, D. and G. show immunoblot analysis to verify knockdown of respective genes. 
B, E. and H. PPAT, PAICS and PKM2 knockdown in A549 cells exhibit reduced cell proliferation. Asterisk indicates data is statistically 
significant (P < 0.05). The solid black line is for Non-specific target (Non-T) siRNA, the dashed line is for siRNA1, and dotted line is for 
siRNA2. C, F. and I. represent Boyden chamber matrigel invasion assay. Photomicrographs of invaded cells (purple) are shown in inset. 
For proliferation and invasion experiments, mean (n = 3) +/− SD is shown. Values with P <0.05 has been considered significant and marked 
with asterisk (*).
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Figure 4: Modulation of PPAT and PAICS or glutamine treatment alters pyruvate kinase (PK) activity. A, B. and C. 
PK activity measured in PKM2, PPAT and PAICS knockdown A549 lung adenocarcinoma cell lines. Inset shows immunoblot confirming 
specific knockdown of the respective genes. D. Measurement of PK activity in A549 cells following treatment with RPMI+10% FBS, no 
glutamine and glutamine (0.5 mM and 2 mM) treatments. E. Immunoblot analyses of PPAT, PAICS and PKM2 following various treatments 
for 48 hrs. β-actin and total H3 were used as loading controls. F. Measurement of PK activity in A549 cells following treatment with 
glutamine (2 mM) and increasing concentration of DON after a period of 48 hrs. G. Immunoblot analyses with PPAT and PAICS in A549 
cells following treatment with glutamine (2 mM) or increasing concentration of DON after 48 hrs. Minus glutamine has been considered as 
negative controls and β-actin has been used as loading control.
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(Fig.5C and 5E, respectively) and PAICS (Fig. 5D and 5F, 
respectively) knockdowns compared to the control cells, 
demonstrating that PPAT and PAICS play essential role in 
lung tumor growth in vivo.
Our data demonstrate (Fig. 5G) that PPAT and 
PAICS of de novo purine biosynthesis show increased 
expression in lung cancer compared to normal lung. PPAT 
and PAICS are two such genes that are co-transcribed 
from locus 4q12 and show genomic amplification in small 
percentage of lung cancer cases. Furthermore, our stud-
ies show that PPAT and PAICS play an oncogenic role in 
lung tumorigenesis. In addition, we show that PPAT and 
PAICS expression levels and pyruvate kinase activity are 
modulated by glutamine. Finally, PPAT and PAICS [24] 
levels regulate pyruvate kinase activity that is comparable 
to PKM2 depletion. This could possibly be through modu-
lating levels of SAICAR, the PAICS enzyme product that 
directly interacts and activate PKM2 activity [24]. Further 
studies are needed to understand the exact mechanisms by 
which PPAT and PAICS modulate PK activity in normal 
glucose medium.
DISCUSSION
Recent reports from the World Health Organization 
warns of a dramatic global rise in cancer incidence and 
related mortality [52]. Lung cancer, which accounts for 
the most cancer-related deaths, is a heterogeneous dis-
ease and a leading cause of cancer-related mortality in the 
United States [1]. Non-small cell lung cancer (NSCLC) 
accounts for 90% of lung cancer while small-cell lung can-
cer (SCLC) accounts for the remainder [6]. Advancement 
in whole genome, exome and transcriptome sequencing 
technology has led to the stratification of lung cancer 
into specific molecular subtypes based on mutations they 
harbor [5]. For example, as discussed earlier, mutation 
in EGFR accounts for 10–30%, KRAS for 15–30%, and 
FGFR1 for 20% of NSCLC and targeted therapies against 
specific mutations has proven clinically more beneficial 
to patients compared to the cytotoxic chemotherapies [4]. 
Unfortunately, >50% of NSCLC harbor no targetable 
oncogenic driver mutations and many are usually diag-
nosed at an advanced stage. The intractable nature of lung 
cancer necessitates search for early diagnostic markers and 
identification of relevant therapeutic targets to improve 
patient prognosis. We showed that PPAT and PAICS of 
de novo purine biosynthesis are up-regulated in lung ade-
nocarcinomas. Importantly, these genes are amplified in 
a subset of lung cancer cell lines as well in primary lung 
tumors. Of clinical significance is our observation that 
PPAT, PAICS and PKM2 (isoform of the PKM gene) tran-
script levels correlate with patient survival, differentiation 
status and smoking status. Furthermore, we also showed 
that PAICS protein expression predicts disease outcome. 
As indicated earlier, a clear molecular stratification has 
been instrumental in early detection and precise therapeu-
tic regimen. In addition, we showed the critical role of 
PPAT and PAICS in lung cancer progression both in vitro 
and in vivo. Our study therefore reveals that PPAT and 
PAICS genes as potential therapeutic targets.
The PKM gene expresses two isoforms, PKM1 and 
PKM2 both differing by presence of a single exon in a 
mutually exclusive manner [25, 53]. An earlier study has 
shown correlation of high PKM2 levels and poor prog-
nosis and demonstrated in vitro and in vivo role in lung 
cancer [54]. We demonstrated that specific knockdown 
of the PKM2 isoform dramatically reduces cell prolifera-
tion in wider spectrum of lung cancer cell lines including 
lung adenocarcinomas and large cell carcinoma. Recently 
SAICAR, the intermediate metabolite of the enzyme 
PAICS was shown to allosterically activate PKM2 activ-
ity under glucose depleting conditions [24] and mediate 
ERK1/2 phosphorylation thereby induces cancer cell 
proliferation [55, 56]. Interestingly, we discovered that 
PPAT and PAICS knockdown substantially diminished 
pyruvate kinase activity that is comparable to the PKM2 
knockdown suggesting that PKM2 could be an important 
contributor of the pyruvate kinase activity in lung cancer 
cell lines. PKM2 isoform expression which is predominant 
in cancers, exists as both dimer and tetramer and plays 
a role in tumorigenesis in both forms [57]. Our study 
confirms increased PKM2 expression in lung cancer and 
regulation of pyruvate activity by de novo purine pathway 
genes can alter metabolic status and promote oncogenesis 
of lung cells. The oncogenic role of PPAT and PAICS that 
we observed therefore could be because of direct contribu-
tion to purine supply for efficient DNA replication during 
S-phase, as observed by our cell-cycle analyses and poten-
tiating pyruvate kinase possibly through PKM2 activity.
De novo purine biosynthesis utilizes charged ribose-
5-phosphate, known as phosphoribosyl pyrophosphate 
(PRPP) and glutamine as substrates by PPAT in the first 
committed step. Glutamine, a non-essential amino acid 
for normal cells, is essential for neoplastic transforma-
tion. Moreover most of the cancer cells won’t survive 
in the absence of exogenous glutamine, and show gluta-
mine addiction [58]. Recent study has shown that NSCLC 
cells show glutamine dependency [59]. Our studies con-
firmed that glutamine strongly effects lung cancer cell 
growth as well as in regulating pyruvate kinase activity. 
We showed that glutamine deprivation reduces PPAT and 
PAICS expression. Glutamine has multi-faceted function 
in cancer metabolism; including as primary carbon source 
replacing glucose [45, 58]. Substantial evidence suggests 
that increased uptake of glutamine in cancer cells under-
goes the anapleurotic pathway, where it is converted into 
glutamate and then α-ketoglutarate (α-KG), a key interme-
diate in the tricarboxylic acid cycle [21]. We also observed 
that glutamine mediated induction of PPAT and PAICS 
expression and PKM2 activity which could be reversed 
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by glutamine antagonist L-diazo-5-oxo-L-norleucine 
(DON). Glutamine dependency has been demonstrated 
in multiple cancers [58]. Direct targeting of glutamine 
 dependency by  administration of glutamine analogues such 
as DON, azaserine and acivicin showed their strongest 
effects on nucleotide biosynthesis [45]. These glutamine 
 analogues showed potent anti-neoplastic effects in vitro 
[48].  However, efforts to incorporate them in clinical set-
tings were stymied because of neurotoxicity, GI toxicity 
and myelosuppression [45, 58]. A concerted effort was 
Figure 5: Stable knockdown of PPAT and PAICS reduces tumor growth in xenograft models. A. PPAT and B. PAICS 
knockdown using two independent shRNAs were utilized in the in vivo chicken chorioallantoic membrane (CAM) assay. Tumor growth 
was measured in PPAT and PAICS stable knockdown cells as well as in control A549 non-targeting shRNA cells (adenocarcinoma). Tumor 
size plotted correspond to average tumor size of 8 eggs per group and +/− SE per group (n = 8). C–F. Athymic nude mice were injected 
with A549 cells that had stable PPAT and PAICS knockdown separately and tumors were monitored over four weeks (C and D respectively); 
following which the mice were sacrificed and tumor weights were measured (E and F respectively). Non-targeting shRNA was used as 
control. The solid black line is for Non-T shRNA, the dashed line is for shRNA1 and dotted line is for shRNA2. Each value is tumor mean 
(n = 16) +/-SE from 8 mice; P <0.05 is considered as significant. G. Our study showed increased expression of de novo purine biosynthesis 
pathway genes PPAT and PAICS in lung cancer, their regulation by amplification and through induction by glutamine. This study also 
shows a role for PPAT and PAICS in lung tumorigenesis. Glutamine analog DON blocks the glutamine mediated induction of PPAT and 
PAICS. Increased expression of PPAT and PAICS modulates PK activity possibly by influencing levels of SAICAR [24], the product of 
PAICS in cancer cells. These enzymes therefore serve as effective therapeutic targets.
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made to circumvent toxicity issues by blocking gluta-
mine availability to cancer cells either through inhibiting 
its uptake using GPNA(γ-L-glutamyl-p-nitroanilide) in 
lung cancer [60], or preventing its synthesis by inhibiting 
glutamine synthase using inhibitors such as BPTES(Bis-
2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl)ethyl sulfide) 
[61], compound 968 [62] and L-asparaginase [63]. Knock-
ing down SLC1A5 [Solute Carrier Family 1 (Neutral 
Amino Acid Transporter), Member 5], the glutamine trans-
porter has been demonstrated to inhibit tumor formation in 
acute myeloid mouse xenotransplant model [63]. Our study 
further illustrates the important role played by glutamine 
in inducing de novo purine biosynthetic genes PPAT and 
PAICS. We suggest that oncogenic effects of glutamine can 
be mitigated by potentially interfering with de novo purine 
biosynthesis pathway genes such as PPAT and PAICS or 
PKM2 activity. Inhibiting de novo purine pathway and 
PKM2 activity would also circumvent toxicity issues 
associated with glutamine antagonists as these genes are 
overexpressed in cancer cells.
In summary, we identified increased expression of 
PPAT and PAICS in de novo purine biosynthetic pathway 
that is potentially useful for lung cancer prognosis. Our 
studies indicated that both genes are amplified in a fraction 
of lung cancer patients. We demonstrated the functional 
significance of PPAT and PAICS during oncogenesis 
through several in vitro and in vivo studies and their role 
in regulating PKM2 activity. We established glutamine-
mediated induction of PPAT and PAICS as an important 
metabolic event for increased expression of these genes 
during lung oncogenesis, which in turn enhances tumor-
specific pyruvate kinase activity. Altogether, these results 
identify potentially novel targets for therapeutic interven-
tion to treat lung cancer.
MATERIALS AND METHODS
Patient samples
We used frozen primary tumors and matched 
 non-malignant lung samples from lung adenocarcinoma 
patients who underwent resection at the University of 
Michigan Health System from 1991–2007. Informed 
consent was obtained for each subject and clinical investi-
gations were conducted after approval by the Institutional 
Review Board. Tumor specimens were immediately fro-
zen following resection and stored at −80°C. Regions 
containing a minimum of 70% tumor cellularity were 
used for RNA/protein isolation. Tumor grade assessment 
as well as  histopathological analysis of sections adjacent 
to regions used for RNA isolation was performed accord-
ing the IASLC/ATS/ERS International Multidisciplinary 
Classification of Lung Adenocarcinoma [64, 65]. None of 
the patients included in this study received preoperative 
 radiation or chemotherapy. Clinical data was  retrospectively 
collected from the medical records and all cases were 
staged according to the revised 7th TNM classification 
criteria [65]. The median follow-up time was 8.12 years 
among the patients that remained alive.
Primary tumor-derived gene expression data sets
Two published Affymetrix microarray data sets 
were used in the survival analysis for genes PPAT, 
PAICS and PKM2 [35, 40]. The CEL files of microar-
ray data were normalized using Robust Multi-array 
Average (RMA) method. The patient characteristics for 
Shedden et al, 442 tumors are provided in Supplementary 
Table S1. Overall survival is the outcome for all datasets, 
and it is censored at 5 years.
Cell line treatments
The cell lines used in this study were purchased from 
ATCC, USA. Lung cancer cell lines A549, H23, H661 and 
H838 were grown in 10% FBS-RPMI 1640 (Life Technol-
ogies, CA) in 5% CO2 cell culture incubator. The reagents 
L-glutamine and L-diazo-5-oxo-L-norleucine (DON) are 
purchased from Sigma-Aldrich, USA. As described else-
where [60, 66, 67], for glutamine studies, the cells were 
plated in 6-well tissue culture plates at a density of 0.2 mil-
lion cells/well. The following day, the cells were washed 
twice with serum free glutamine-free medium and replaced 
with 10% dialyzed FBS containing glutamine-free RPMI 
1640 (Life Technologies, CA), and then incubated for 48 
h. The corresponding glutamine-replete medium was pre-
pared by addition of indicated concentration of glutamine. 
For DON (a glutamine analogue) studies, we added indi-
cated concentration of DON to the cells which are already 
in 10% dialyzed FBS + 2 mM Gln+ RPMI 1640 medium 
[68, 69]. Bronchial lung epithelial cells, BEAS-2B were 
grown in BEBM medium with supplements (Lonza, 
USA). Adenoviruses and lentiviruses were generated by 
the University of Michigan Vector Core. Lung cancer cells 
were infected with lentiviruses expressing PPAT shRNAs, 
PAICS shRNAs or Non-target controls only, and stable cell 
lines were generated by selection with 1 μg/ml puromycin 
(Life Technologies, CA).
Pyruvate kinase activity assay
The pyruvate kinase activity was measured using 
Pyruvate Kinase Assay kit (Biovision, Catalog #K709-100). 
Briefly, cell pellets were suspended in 4x assay  buffer 
(10,000 cells/100 μl). The lysed cells were spun 
(10,000 rpm/5 mins) to clear cell debris and cell super-
natant was used to measure pyruvate kinase activity 
colorimetrically (λ = 570 nm) using 96 well-plate assays. 
The PK activity as measured by pyruvate production was 
calculated using standard PK activity provided by the kit. 
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The calculated activity was then normalized to protein 
concentration of the cell lysate and plotted. The y-axis 
represents the percentage normalized PK activity (% μmol 
pyruvate produced/mg of protein).
Immunoblot analysis
For immunoblot analysis, 10 μg of lung adenocarci-
noma tissue lysates from regions >70% tumor cellularity 
and matched normal tissue lysates were used. Tissue and 
lung cancer cell line lysates were boiled in sample buf-
fer, separated by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis, and transferred onto polyvinylidene 
difluoride membrane (GE Healthcare, Piscataway, NJ). 
First lane contains 5 ul of spectra multicolor broad range 
protein ladder (Life Technologies, CA). The membrane 
was incubated for 1 hour in blocking buffer (TBS, 0.05% 
Tween, 5% nonfat dry milk) and incubated overnight at 
4°C with respective primary antibodies, and signals were 
visualized after incubating with secondary antibody con-
jugated with HRP. The list of various antibodies, catalogue 
numbers and dilutions used are mentioned in Supplemen-
tary Table S2.
RNA and DNA isolation and quantitative real-
time PCR assays
Total RNA was isolated from tissues and cells 
using RNeasy Mini Kit (Qiagen, USA). Quantitative 
PCR (qRT-PCR) with cDNA (Applied Biosystems, USA) 
was performed with 10 ng of cDNA used as template and 
quantified using SYBR (Applied Biosystems, USA). qRT-
PCR assays were performed in triplicate. Both PKM1 and 
PKM2 qRT-PCR primers were taken from elsewhere [43].
The primer sequences for the transcript analyzed by SYBR 
green qRT-PCR as provided in Supplementary Table S3.
Immunohistochemistry of TMA
Immunohistochemistry on lung adenocarcinoma tissue 
microarray was performed using PPAT mouse  monoclonal 
antibody, PAICS mouse monoclonal antibody and PKM2 
specific rabbit monoclonal antibody. Immunohistochemis-
try was performed using an automated protocol developed 
for the DISCOVERY XT automated slide  staining system 
(Ventana Medical Systems, Inc.,) using Ultramap anti-mouse 
HRP or Ultramap anti-rabbit HRP as secondary antibody and 
was detected using ChromoMap DAB (Cat#760-159,  Ventana 
Medical Systems Inc.,) Hematoxylin II (Cat#790-2208 
 Ventana-Roche, Tucson, AZ, USA) was used as the counter-
stain. Immunohistochemistry staining was evaluated by D.T. 
TMA sections were scored for the proportion of tumor cells 
staining for the marker and intensity using the  methodology 
described by Harvey et al [70].
Fluorescence in situ hybridization (FISH)
BAC clones were used to generate the locus specific 
(4q12) FISH probe for PAICS and PPAT (RP11-393M11) 
and chromosome 4 control probe (RP11-719O22). All 
clones were tested on normal human metaphase chromo-
somes to validate map position. PAICS locus probe and 
chromosome 4 control probes were detected with anti-
digoxigenin fluorescein Fab fragments to yield green 
color and Streptavidin Alexa fluor 594 to yield red color, 
respectively. 200 ml overnight cultures for each BAC 
clone were grown in LB medium containing 12.5 μg/ml 
of chloramphenicol at 37°C for 14–16 hours with constant 
shaking. DNA was prepared using Qiagen-midiprep kit 
using Qiatip-100 according to the protocol provided by 
the manufacturer (Qiagen, USA).
All FISH probes were prepared by nick transla-
tion labeling using modified nucleotides conjugated with 
biotin or digoxigenin utilizing biotin nick translation 
mix (Cat# 11745824910, Roche, USA) for chromo-
some 4 control probe; digoxigenin nick translation mix 
(Cat# 11745816910, Roche, USA) for PAICS locus probe, 
respectively. Probe DNA was precipitated and dissolved 
in hybridization mixture containing 50% formamide, 
2XSSC, 10% dextran sulphate, and 1% Denhardt’s solu-
tion. Approximately 200ng of each labeled probe was used 
for hybridization. Fluorescent signals were detected with 
Streptavidin Alexa fluor 594 (Cat# S-32356, Invitrogen, 
USA) and anti-digoxigenin fluorescein Fab fragments 
(Cat# 11207741910, Roche, USA) for red and green 
colors, respectively. FISH scoring was performed by an 
experienced cytogeneticist (NP). Copy number was evalu-
ated based on the ratio between control and locus specific 
probe. Copy number 4 or above are considered as amplifi-
cation in at least 15–20% of the cells in the tumor samples. 
Fluorescent images were captured using a high resolution 
CCD camera controlled by ISIS image processing soft-
ware (Metasystems, Germany).
siRNA transfections
Custom made small interfering RNA (siRNA) 
duplexes for RNA interference of PPAT, PAICS were 
purchased from Dharmacon, Lafayette, CO (GE 
Healthcare, USA). PKM2 specific siRNA was custom syn-
thesized from Dharmacon, Lafayette, CO (GE Healthcare, 
USA) [43]. The list of siRNAs, shRNAs and the catalogue 
numbers are mentioned in Supplementary Table S4. Trans-
fections were performed with either oligofectamine (Life 
Technologies, USA) or Lipofectamine® RNAimax (Life 
technologies, USA). Seventy-two hours after the siRNA 
transfections, the cells were harvested for RNA isolation 
or lysed for immunoblot analysis. Short hairpin RNA 
(shRNA) constructs were generated using pGreen-puro 
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vector (System Biosciences, Mountain View, CA). For 
PPAT knockdown, the pGIPz plasmids were obtained from 
Dharmacon, Lafayette, CO (GE Healthcare, USA). All the 
lentiviruses were generated by the University of Michigan 
Vector Core.
Cell proliferation assays
Cell proliferation was measured by cell counting. 
For this, stable and/or transient PAICS, PPAT and PKM2 
knockdowns were used. Around 10, 000 cells/well were 
seeded in 24-well plates (n = 4), after transfecting either 
with specific siRNA duplex or stable knockdowns as 
described above. Stable knockdown of PAICS was per-
formed using shRNA strategy using lentiviral construct 
with specific duplex sequences targeting PAICS. These 
stable knock down cells were plated at same density as 
mentioned earlier, harvested and counted at specified time 
points by Coulter counter (Beckman Coulter, Fullerton, 
CA). Non-targeting siRNA or shRNA-treated cells were 
served as controls. For glutamine studies, as mentioned 
earlier lung cancer cell lines were seeded in same density 
in glutamine-free medium and counted the cells after each 
indicated time point. Each experiment has been carried at 
thrice with four replicates in each experiment per sample. 
Data shown is representative figure of one such experiment.
Cell cycle analysis
siRNA treated cells (as mentioned earlier) were 
trypsinized and resuspended in 0.5 ml of PBS at a concen-
tration of 106cells/ml. Ice-cold absolute ethanol was added 
in equal volumes to the sample. The sample was incubated 
for minimum of 20 min, followed by spin at 2000 rpm 
for 2–5 min. Ethanol was decanted and cell pellet was 
resuspended in 0.5 ml propidium iodide+RNase solu-
tion and incubated at room temperature for minimum of 
20 min in dark. The cell cycle analysis was carried through 
flow cytometry core facility, University of Michigan, Ann 
Arbor. Each experiment has been carried at twice in trip-
licate per sample. Data shown is representative figure of 
one such experiment.
Matrigel invasion assay
For invasion assays, transiently transfected or stable 
knockdown of PPAT, PAICS and PKM2 in were used in 
A549 cells. BEAS-2B (benign transformed lung epithelial) 
cells were infected with PAICS-adenovirus. Seventy-
two hours post-transfection and/or infection, cells were 
seeded onto BD BioCoat matrigel matrix (BD, CA) pres-
ent in the insert of a 24-well culture plate. For A549, 10% 
serum containing RPMI medium was added to the lower 
chamber as a chemoattractant. For BEAS-2B, BEBM 
medium with supplementary growth factors was added 
as  chemoattractant. After 36 h, the non-invading cells and 
matrigel matrix were gently removed with a cotton swab. 
Invasive cells located on the lower side of the chamber 
were stained with 0.2% crystal violet in methanol, air-
dried and photographed. They were then enumerated 
microscopically using multiple representative areas. For 
colorimetric assays, the inserts were treated with 150 μl of 
10% acetic acid and the absorbance measured at 560 nm 
[71]. Each experiment has been carried twice in triplicates 
per sample. Data shown is representative figure of one 
such experiment.
In vitro overexpression
PAICS cDNA (Origene, MD; Cat# RC223925) was 
cloned into Gateway expression system (Life Technologies 
CA). To generate adenoviral construct, PCR8-PAICS (flag 
tagged) was recombined with pAD/CMV/V5-Dest™ (Life 
Technologies, CA) respectively using LR Clonase II (Life 
Technologies, CA) [71]. Adenoviruses were generated by 
the University of Michigan Vector Core. Benign lung epi-
thelial cells (BEAS2-B) were infected with adenoviruses 
expressing PA1CS or lacZ for transient over-expression.
Chicken chorioallantoic membrane (CAM) assay
The CAM assay for tumor (or xenograft) forma-
tion was performed as previously described [49, 51, 72]. 
Briefly, fertilized eggs were incubated in a rotary humidi-
fied incubator at 38°C for 10 days. CAM was dropped by 
making two holes, one through the eggshell into the air sac 
and a second hole near the allantoic vein that penetrates 
the eggshell membrane but not the CAM. Subsequently, 
Dremel 3000 Rotary Tool was used to cut a 1 cm2 window 
to expose the underlying CAM near the allantoic vein. 
Approximately 2 million cells in 50 μl of media were 
implanted in each egg, windows were sealed and the eggs 
were returned to the incubator. Following 7-day incubation 
post-tumor cells injection; the primary tumor was excised 
and weighed. Around 8 eggs per group were used in each 
experiment.
Tumor xenograft model
All procedures involving mice were approved by 
the University Committee on Use and Care of Animals at 
the University of Michigan and conform to their relevant 
regulatory standards. To evaluate the role of PPAT and 
PAICS in tumor formation, we propagated stable PPAT 
and PAICS knockdown A549 pools using two-independent 
shRNAs, and Non-targeting shRNA control cells and inoc-
ulated 1 × 106 cells subcutaneously into the dorsal flank of 
4-week-old male athymic nude mice (Foxn1nu) (n = 8 for 
each group; Harlan Laboratories, USA). Tumor size was 
measured biweekly, and tumor volumes were calculated 
using the formula (π/6) (L × W2), where L = length of 
tumor and W = width and represented as mm3/tumor. Post-
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monitoring, tumors were dissected out, photographed and 
weighed. Tumor weight is represented in mg/tumor.
Statistical evaluation
For cell lines and pyruvate kinase assays represen-
tative readings in triplicate was averaged and plotted in 
various graphs. The error indicates the standard deviation 
(SD) in case of colorimetric assays and cell counts. In case 
of tumor grafts, the error bars represent standard error 
(SE) instead of SD. For CAM assays, 8 eggs have been 
used per treatment while for mice experiments, values 
represent average of 8 mice/group. Statistical  evaluation 
of the data was carried out using student’s t-test and  values 
that showed P <0.05 were considered significant.
The clinical and pathological characteristics were 
analyzed using the Student’s t-test for comparing two 
groups and by ANOVA for multiple group compari-
sons, with P < 0.05 considered statistically significant. 
For values that were not normally distributed the 
Mann-Whitney rank sum test was used. Univariate and 
multivariate (adjusted by age, gender, stage and differ-
entiation) Cox proportional hazards regression model 
were used for continuous values of each gene; Kaplan-
Meier survival curve and log-rank test were used to 
separate patients into three risk tertiles (high, medium, 
and low-risk, 1/3rd in each group) based on gene/protein 
expression levels.
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